Related Experiment Videos
Anomalous dystroglycan in carcinoma cell lines
C Losasso1, F Di Tommaso, A Sgambato
1Centro Chimica dei Recettori (CNR), Istituto di Chimica e Chimica Clinica, Università Cattolica del Sacro Cuore, Rome, Italy.
FEBS Letters
|November 18, 2000
Summary
Dystroglycan, a key cell receptor, is found to be truncated in various cancer cells. This truncation results in an abnormal beta-dystroglycan protein, impacting cell interactions.
Area of Science:
- Cell Biology
- Biochemistry
- Cancer Research
Background:
- Dystroglycan is a vital receptor mediating cell adhesion and communication.
- It links the extracellular matrix to the intracellular cytoskeleton.
- Dysfunctional dystroglycan is implicated in various diseases.
Purpose of the Study:
- To investigate the integrity of dystroglycan in different cell types, particularly in cancer.
- To identify potential alterations in dystroglycan structure and expression in malignant cells.
Main Methods:
- Western blotting to detect beta-dystroglycan protein.
- Analysis of protein extracts from normal and cancerous cell lines (human and murine).
- Reverse transcriptase polymerase chain reaction (RT-PCR) to assess gene expression and splicing.
Main Results:
- Normal cells exhibited a 43 kDa beta-dystroglycan band, while cancer cells showed an anomalous ~31 kDa band.
- Alpha-dystroglycan was undetectable in most cell lines with the truncated beta-dystroglycan.
- Truncated beta-dystroglycan was also observed in chemically induced rat mammary tumors.
- RT-PCR confirmed no alternative splicing or novel isoforms were responsible for the truncated form.
- Both 43 kDa and ~31 kDa beta-dystroglycan forms contain their transmembrane segment.
Conclusions:
- Dystroglycan undergoes truncation in various human cancer cell lines and in induced rat mammary tumors.
- This truncation affects both alpha- and beta-dystroglycan subunits.
- The findings suggest a novel mechanism of dystroglycan dysfunction in cancer development.